Report an error
Spotted something inaccurate in “Lecanemab Shows Cost-Effectiveness Edge Over Aducanumab for Early Alzheimer's”? Tell us what’s wrong and we’ll check it against the original source.
This form is for factual corrections. We read every report but cannot reply individually.